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Few cancers generate as impassioned debate about treatment as does malignant pleuralmesothelioma (MPM). The relative merits of surgery, radiation, and chemotherapy are
endlessly discussed, often with limited scientific evidence to support strongly held
viewpoints. One of the perennial controversies in the treatment of MPM is whether
extrapleural pneumonectomy (EPP) is more effective than less extensive operations such
as pleurectomy/decortication (P/D) in patients who are candidates for surgical resec-
tion.1–3 EPP offers the benefit of complete resection of all gross tumor and permits the
delivery of high-dose adjuvant hemithoracic radiotherapy (RT) but is associated with
greater morbidity and mortality than lesser operations. Moreover, despite the excellent
local control provided by EPP and hemithoracic RT, many of these patients experience
rapid progression of disease in distant sites and have a limited life expectancy.4,5 The
Mesothelioma and Radical Surgery (MARS) trial reported in this issue of the Journal of
Thoracic Oncology is an effort to determine the potential benefit (or lack thereof) of EPP
in the treatment of MPM. Led by Mr. Tom Treasure,6,7 who has been a vocal critic of the
lack of randomized controlled trials in MPM, this multicenter study from the United
Kingdom was open to patients whose extent of disease and overall medical condition
permitted consideration of multimodality therapy and EPP. Patients first consented to
receive induction chemotherapy and if they completed that treatment successfully, were
then potentially consented to randomization between EPP versus no surgical intervention.
The study end point of this first MARS trial was to determine whether patients would
agree to being randomized to surgery versus no surgery. The trial successfully met its
accrual goal of 50 randomized patients. The design of a second trial is currently under
discussion.8
The demonstration that patients and their physicians will agree to a randomization
between two very different treatments, i.e., EPP versus no resection, is an important
achievement and sets the stage for a subsequent trial that will answer a therapeutic surgical
question definitively. Although physicians in other countries can certainly be criticized for
not undertaking similar randomized trials, oncologists and surgeons in the United
Kingdom are perhaps uniquely positioned to perform the MARS trial by virtue of disease
incidence, geography, and the British national health care system. As indicated by the
authors, the United Kingdom now has the highest incidence of MPM in the world. By
comparison, the United States has a similar number of MPM cases annually but scattered
across a much larger population and geographical area. Unlike the more common cancers
the current treatment strategies for MPM, especially with respect to surgery and RT,
require highly specialized expertise that is not widely available in the community setting.
Indeed, as noted by the authors, experience gained during this trial improved the expertise
of multidisciplinary oncologic teams in centers of excellence in diagnosing, staging, and
treating MPM. For the small numbers of MPM patients scattered across large geographic
areas in countries such as the United States, access to complex multimodality therapy
within or outside of clinical trials is often not available. The health care system in the
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United Kingdom is also particularly well suited to trials in
MPM. Although the United States (as one example) has
highly fragmented health insurance coverage with many
health care organizations refusing to support patient partici-
pation in clinical trials, as well as multiple clinical trial
groups that sometimes pursue competing agendas, and no
system for the regionalization of oncologic care, the United
Kingdom has national health care insurance, a single major
source of funding for cancer clinical trials and a system for
the potential regionalization of care for rare diseases into
centers of excellence. Illustrating these differences, this re-
port indicates that more than 300 patients were screened by
only 11 participating centers, that surgery was performed by
only five centers and that RT was provided by only 10
centers. This concentration of eligible patients and health care
providers enhances the chances of successfully completing a
randomized trial of complex design for a rare malignancy.
Finally, participation in a study such as the MARS trial
demands equipoise on the part of both physicians and patients
about two treatments that are conceptually very different.
Evidently, there has been sufficient equipoise in the United
Kingdom to permit successful accrual to the MARS trial.
Whether a similar degree of equipoise could be achieved in
other countries that potentially have different views of MPM
and its treatment remains an open question.
Experience from this first MARS trial raises issues that
are relevant to the design of the next trial. Two aspects of
study design seem to have been particularly effective in this
first trial, namely the use of a virtual multidisciplinary team to
review patient eligibility and the two stage consent process. It
would probably be beneficial to retain both of these compo-
nents in the next trial. Differences in survival observed in this
small group of 50 patients (presumably the subject of future
analyses) will obviously help to establish the sample size
necessary for a randomized trial asking a therapeutic ques-
tion. The authors proudly point out that 45% of the patients
eligible for surgery after chemotherapy underwent random-
ization. However, these 50 patients were drawn from a pool
of more than 300 patients who were originally screened for
the trial. This considerable drop out rate will need to be
considered in planning the next trial since potentially the
number of patients who need to be screened for the study may
be six times the number of patients ultimately randomized. It
would be useful to require screening logs in the next trial to
determine whether the drop out rates have changed over time.
This trial did not stratify for known prognostic factors includ-
ing tumor histology or T, N, and overall stage or positron
emission tomography standardized uptake value. Adding
these important stratification factors to the next trial will, of
course, increase the sample size and affect the feasibility of
the next trial. Conversely, in this first trial, patients who had
biopsy-proven N2 disease were excluded. The rationale for
this exclusion is unclear because this group of patients is at
high risk for systemic disease progression and may benefit
significantly from a combined modality approach that starts
with induction chemotherapy.9–11 Including such patients, but
stratifying for N stage, may improve accrual to the next trial
and will answer an important secondary end point.
This report does not indicate whether there was any
standardization of the induction chemotherapy regimens or of
surgical and RT techniques. Such standardization will be
important in a randomized trial testing a therapeutic question.
Some limitations need to be placed on the types and doses of
induction chemotherapy regimens allowed. In addition, there
can be considerable variation in the approaches used for EPP
and in surgical morbidity and mortality, even across a small
number of institutions. Key elements of the operation need to
be codified by participating surgeons. Institutional or sur-
geon-related differences in surgical adverse events that may
be apparent from this first MARS trial need to be addressed
in designing the next trial. RT technique and dose also affect
the risk of serious adverse events and need to be carefully
specified. Standard approaches for collecting adverse event
data need to be implemented across the entire duration of
patient treatment and follow-up. Surgical complications are
often recorded separately from chemotherapy and radiation-
related adverse events and reported in a nonstandardized
manner. Use of the internationally accepted Common Termi-
nology Criteria for Adverse Events for the reporting of all
adverse events including surgical complications would pro-
vide the best means of comparing morbidity and mortality
between two study arms in the next trial. It will also be
important to examine late as well as early adverse events.
Finally, the next MARS trial offers the opportunity to study
two additional issues in MPM patients undergoing complex
multimodality treatment: quality of life and tumor biology.
There are few quality of life studies in MPM patients and
quality of life endpoints may become important if the differ-
ences in survival between two study arms are not significant.
The body of knowledge about MPM tumor biology is still
modest and a prospective randomized therapeutic trial offers
a superb opportunity to collect tumor tissue before and after
induction therapy and to correlate molecular abnormalities
with a rich and highly reliable clinical database. Again, in a
geographically small area such as the United Kingdom with
a small number of participating centers, acquisition, and
centralized storage of tumor tissue should be straightforward.
In the Discussion section of the report, the authors hint
that recent studies suggesting that EPP and P/D may be
associated with similar overall survival have led them to
rethink what operation would be performed in the surgical
arm of the next trial.3,12–14 This is unfortunate. The authors
correctly point out that the data regarding the relative impact
of EPP and P/D are retrospective and therefore cannot pro-
vide definitive evidence on this topic. Other issues, including
a staging system for MPM which is rudimentary, and our
relative ignorance of prognostic factors and tumor biology,
make it difficult to assess surgical treatments reliably in
retrospective studies. With the successful completion of the
first trial, the MARS investigators are uniquely positioned to
perform a definitive therapeutic trial that will answer a highly
controversial question, namely whether EPP adds to nonsur-
gical therapy. Muddying the waters by asking a different
surgical question or allowing multiple operations within the
trial will lead to unclear results. If the MARS investigators do
not avail themselves now of the opportunity to define the role
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of EPP, this therapeutic question may never be answered. If the
next MARS trial successfully defines the role of EPP, subse-
quent trials can be designed to test the role of other surgical
procedures such as P/D. It is vitally important that the MARS
investigators finish what they have so admirably begun.
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